When Strong Technology Met a Niche Market

A surgical device for a rare, life-threatening condition showed strong clinical results — but high trial costs and a limited patient pool made it difficult to attract investment. Xythena stepped in to reframe the opportunity, positioning the device as a system-level value driver, securing FDA Breakthrough Device Designation, and structuring a phased capital strategy. Within 12 months, the company raised $2M and launched a focused trial. By 24 months, it had partnered with leading institutions on expanded trials and was on track for follow-on investment.

Story | Fundraising | Go-to-Market

When a Breakthrough AI Model Made No Impact

A breakthrough AI model showed strong potential in detecting early signs of patient deterioration — but hospitals weren’t using it. Despite promising results, it sat idle, misaligned with workflows and disconnected from clinical priorities. Xythena stepped in to anchor the model to a high-impact use case, translate outputs into trusted clinical signals, and build the structure for adoption. Within months, it was in use and showing results. Within a year, it had expanded to new units and use cases — as a trusted early warning tool.

Story | Roadmap | Go-to-Market

When Early Wins Didn’t Open Bigger Doors

A virtual care platform had strong early adoption but struggled to scale. Despite clinical success, it wasn’t landing with enterprise buyers or expanding beyond pilots. Xythena repositioned the product around system-level value, revamped the go-to-market strategy, and structured a strategic partnership with a global medtech company. Within a year, the platform launched through joint channels and began gaining traction as part of enterprise virtual care platform.

Roadmap | Go-to-Market | Scale

When a Big Contract Put Delivery at Risk

After landing a major national contract, a care coordination platform needed to scale its delivery fast — but execution started to crack. Sprints slipped, ownership blurred, and engineering momentum stalled. Xythena stepped in to close the gaps. We clarified technical ownership, rebuilt the sprint cadence, and introduced lightweight structure to restore delivery flow. Within months, the team was shipping critical integrations on time, reducing rework, and operating with confidence — even as volume  doubled.

Scale | Operation

When Policy Change Erased the Market

A sudden policy shift wiped out demand for the company’s direct-to-consumer health product — effectively eliminating its core market. Xythena stepped in to lead a full strategic pivot to the public sector. We redefined the business model, rebuilt the product for institutional buyers, and established a new path to traction and exit. Within eight months, the company signed its first government contract. Three years later, it was acquired by a national insurer — with a public-sector position that made the deal possible.

Pivot | Story | Operation